The Food and Drug Administration announced Wednesday that it has approved daraxonrasib, a new oral medication to be marketed under the brand name Rasonque by Revolution Medicines. The approval applies to adults with metastatic pancreatic adenocarcinoma who have already received at least one line of systemic therapy.
Clinical trial shows dramatic survival benefit
In a late‑stage trial involving 500 patients, the median overall survival for those taking Rasonque was more than 13 months, nearly double the 6.7‑month median survival observed in patients who continued with standard chemotherapy. The study’s results were described by investigators as “unprecedented” for a disease that historically offers few effective options.
Why pancreatic cancer remains a deadly challenge
Pancreatic adenocarcinoma accounts for roughly 3.2% of all cancer diagnoses in the United States, yet it represents a disproportionate share of cancer deaths. Late detection, an aggressive disease course, and limited treatment choices have long hampered patient outcomes, according to the FDA.
Regulatory pathway accelerated under the Trump administration
The drug received a Breakthrough Therapy designation in June 2025, a status that speeds development and review for therapies showing substantial improvement over existing treatments. The application was evaluated through the Commissioner’s National Priority Voucher Program, a process initiated by former FDA Commissioner Dr. Marty Makary. Review time was shortened from the usual twelve months to ten months, reflecting the administration’s commitment to fast‑track life‑saving treatments.
Expert commentary
Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at the Dana‑Farber Cancer Institute, called the approval “an exceptional moment for patients with pancreatic cancer and the culmination of many years of research to find a way to target KRAS.” He added that the new option “brings hope to patients with metastatic disease while giving us a foundation to make many more advances against this difficult disease.”
Dr. Angelo de Claro, director of the FDA’s Oncology Center of Excellence, noted that the approval was granted six and a half months before the user‑fee deadline, underscoring the agency’s dedication to accelerating access to innovative cancer therapies.
Patient perspective
Patients who participated in the trial have shared their optimism on national media. One participant, Jim, reported that a liver tumor that had spread from his pancreas shrank by about 50% after beginning treatment with Rasonque, describing the result as “incredible news.”
Looking ahead
While Rasonque is the first drug of its class approved for this indication, researchers are hopeful that the targeted approach—aimed at multiple forms of the RAS protein—could be adapted for other hard‑to‑treat cancers. The FDA’s approval marks a significant step forward in the fight against a disease that has long been considered one of the most lethal in oncology.
Original reporting: Allentown News – 6abc Philadelphia — read the source article.
